The Research Industrial Complex Wastes Big Money

By Chris Centeno, MD /

Receive a Regenexx® Patient Info Packet by email and learn why it's a superior regenerative solution.

University Inc

When President Dwight Eisenhower left office, being a former WWII general, he knew all too well how industry was playing the beltway game of milking the DC cash cow. He warned us of a military-industrial complex. A new editorial now warns of a biomedical-research-industrial complex that, like its partner in the Pentagon, wastes more money than it applies to good use. Let me explain.

My Experiences with Stem Cell Research

When I first began to use stem cells clinically as part of an IRB-approved trial in 2005, a lot of basic science research was needed to guide the project. After reviewing the first couple of hundred research papers, a theme began to appear. The basic science in the world of mesenchymal stem cells was often wasteful and repetitive. There seemed to be little coordinated rhyme or reason, with studies appearing to be on random topics.

A great example of this waste is the Hedgehog pathway. First, I have to congratulate the grad student who named this thing, as being a fan of early video games, it’s very cool to have a hard-core science concept named for Sonic the Hedgehog (yes, one of the component parts is named “Sonic”). This is a signaling pathway that’s involved in how cells differentiate and behave. One of the best-studied Hedgehog pathways shows us how a limb develops in an embryo. A disruption of the pathway is also involved in how cancer cells develop from stem cells.

Given all of the important things that the Hedgehog pathway does, it’s certainly reasonable to have a good number of studies figuring out its component parts. Having said that, as of right now, in the US National Library of Medicine, we have 4,458 research articles on this topic. If we make the search terms broader, we have more than 12,000! How many is enough? That’s a good question, but the point is that if this research were being coordinated and focused on one goal, like curing cancer or getting stem cells to do x or y, my guess is that a thousand studies would be too much. And that’s the point—this type of focused research is uncommon.

The Research Industrial Complex

A nice piece on this topic was just published by Seth Augenstein. He brings out that a few brave and important scientists are starting to criticize the scientific establishment for wasting big bucks. For example, Michael Bracken, a Yale epidemiologist, blasted scientific waste at a speech at the National Institutes of Health. He estimates that 87.5% of biomedical-research money is squandered on the disorganized and random studies like the Hedgehog experiments above. He also discussed how wasting these dollars also impacts patients who die while their tax dollars are squandered rather than being used to discover cures. The Lancet recently weighed in on the issue, saying that $200 billion, in 2010 dollars, is likely being flushed down the science toilet per year.

The Problem: The Modern University Is a Business, Just like Coca Cola

When most of us think of universities, we think of ivory towers and kids toiling away studying. The average American today thinks of a university much in the same way that the average middle-age European thought of the church—as having a higher calling. However, is the image in our heads of threadbare academics toiling away for peanuts to solve the world’s problems true?

First, let’s look at the scale. Harvard has over a $4 billion annual budget, Stanford’s is $5.5 billion, and Ohio State’s is $4.7 billion. That makes these universities equivalent-sized businesses to Coca Cola ($4.4 B). More importantly, these universities blow away most US businesses with cash on hand (their endowments). Harvard has $37 billion, Stanford has $22 billion, and OSU has $3.6 billion. In fact, just a handful of the richest universities in the United States have more cash on hand than the federal government at $49 billion (this is operating cash as the feds can obviously print money as needed).

How Does a University Earn Money?

A modern research university earns money in two key ways:

  1. Taking a significant “vig” off of every research dollar. In most universities, this is approximately 35–45% of every grant or research-study dollar that walks in the door.
  2. Patenting discoveries paid for with your tax dollars. Here the university gets a double bite at the apple—once when it takes your tax money from the feds to fund research and then a second time when it patents the discovery and then licenses those patents to university-owned businesses that exploit the discovery.

How University Inc. Interfaces with Stem Cells

University professors generally don’t like that physicians are using stem cells to treat disease. An entire lexicon of negative sound bites has been developed and are used in the news. As I’ve blogged before, I can’t disagree with their recent contention that many physician stem cell clinics are out of control—treating any patient with any disease who has a credit card that clears. Having said that, it’s important to place that university angst over physician stem cell use into perspective—it’s simply bad for business.

As discussed, University Inc. makes its money by taking its vigorish of grant proceeds and by licensing discoveries paid for by your taxes. Physicians using stem cells reduces the income from both. Who needs a thousand basic science studies of the stem cell Hedgehog pathway when we already know what they can do clinically? Who will license a stem cell patent when there are already 1,000 clinics using stem cells? All of this is very bad for University Inc.’s bottom line. Hence, there is no mystery as to why university professors aren’t fond of stem cell clinics.

How Do We Fix University Inc.?

First, it’s important to understand that University Inc. has done some great things. The Bayh-Doyle Act of the 1980s, which allowed universities to make money from licensing patents, did increase the pace of discovery. However, it’s our biomedical grant system that’s broken. Universities should be celebrating and assisting the translation of stem cells from the bench to the bedside, and instead they have done everything in their power to obstruct it. There’s simply more money to be made by throwing up barriers and prolonging basic science research.

Fixing University Inc. needs to start with realigning research priorities at NIH. First, we need to tie continued grant money to real progress in finding cures. This isn’t a new idea. Smart nonprofits like the Michael J. Fox Foundation do this already. Google does it with their research dollars as well. Here’s a plan:

  1. Twenty-five percent of NIH funds go to fund pure basic science. These are the moonshot ideas that aren’t expected to yield fruit, other than through accidental discovery, or might not find cures for many, many years.
  2. Fifty percent of NIH funds go toward 10-year disease-focused research. You must prove that your basic science research has a plan to get to a cure. To get continued funding, you must show real progress toward that cure.
  3. Twenty-five percent of NIH funds go to toward 3-year disease-focused research. You must show that your idea could translate into a clinical cure used in the clinic within 3 years.

This system would get rid of the waste and refocus a generation of scientists toward finding cures for disease rather than churning basic science topics to get grant funding. Scientists and universities that are incentivized this way would look at the best of what’s happening in the clinical use of stem cells today and quickly partner with physicians on 36-month projects toward cures rather than throwing up roadblocks because basic-science grant money is threatened.

The upshot? University Inc. is broken. Given the immense value of the modern university toward making our lives better, it must be fixed if we’re to see all of the fantastic possibilities biomedical research will bring us over the next century. Some brave university professors are sticking their necks out to open a dialogue on how the system can be made better—I applaud their efforts!

Category: Latest News

Leave a Reply

Your email address will not be published. Required fields are marked *

4 thoughts on “The Research Industrial Complex Wastes Big Money

  1. patti allen

    We applaud this Article! Being a recent Regenexx patient, 10 weeks out and, even without insurance chipping in, I am PROUD to be a participant . With my own research, I have concluded — do NOT see a surgeon unless you want to have body parts removed ! That is what keeps them in business. Do your own research and read the newest-proven conclusions before being subjected to the scalpel!
    Living in Columbus, Ohio, home of The Ohio State University, I still had to travel to Cincinnati for my procedure. This was disappointing but certainly substantiates the statements made here. Hopefully someone, somewhere will start looking at the published facts/findings and see that WE THE PEOPLE will do that same instead of taking the word of physicians who are indeed placing BUSINESS ahead of their patients well-being.
    Thank you !

    1. Regenexx Team Post author

      Patti,
      An educated patient is an empowered patient! Really glad to hear you got treated and that you’ve retained all your original parts!

  2. Dan

    I have been hoping that you would write on this topic!! Paul Knoepfler does everything in his power to demonize physicians who are using stem cells in a clinical setting.. Whats most frustrating is he says that these physicians (including Regenexx ) doctors are solely a profit driven business who really doesn’t care about the best interests of the patients. He lumps all stem cell centers into ONE POT.. He goes on to say how deceptive they are to patients all the while he is spreading mis-information about the stem cells getting used in this country causing cancer. He typically cites that recent article about the gentleman who flew all over the world to get EMBRYONIC stem cell treatments.. It is a very sad situation but its like comparing apples to oranges. He is preying on the general public’s lack of knowledge in this area. I very much hope that he reads this blog post and loosens up on this topic!!

    1. Chris Centeno Post author

      Dan, I agree. Yes, there’s lots of abuse out there, but given that we’ve been publishing research and funding our own basic science studies for the last 11 years, Regenexx is different. As stated above, scientists will never let up on this topic until we change the incentives in the system. Right now their incentive is to block clinical use of stem cells because it’s bad for basic science grant funding.

Chris Centeno, MD

Regenexx Founder

Chris Centeno, MD is a specialist in regenerative medicine and the new field of Interventional Orthopedics. Centeno pioneered orthopedic stem cell procedures in 2005 and is responsible for a large amount of the published research on stem cell use for orthopedic applications.
View Profile

Get Blog Updates by Email

Get fresh updates and insights from Regenexx delivered straight to your inbox.

Regenerative procedures are commonly used to treat musculoskelatal trauma, overuse injuries, and degenerative issues, including failed surgeries.
Select Your Problem Area
Shoulder

Shoulder

Many Shoulder and Rotator Cuff injuries are good candidates for regenerative treatments. Before considering shoulder arthroscopy or shoulder replacement, consider an evaluation of your condition with a regenerative treatment specialist.

  • Rotator Cuff Tears and Tendinitis
  • Shoulder Instability
  • SLAP Tear / Labral Tears
  • Shoulder Arthritis
  • Other Degenerative Conditions & Overuse Injuries
Learn More
Cervical Spine

Spine

Many spine injuries and degenerative conditions are good candidates for regenerative treatments and there are a number of studies showing promising results in treating a wide range of spine problems. Spine surgery should be a last resort for anyone, due to the cascade of negative effects it can have on the areas surrounding the surgery. And epidural steroid injections are problematic due to their long-term negative impact on bone density.

  • Herniated, Bulging, Protruding Discs
  • Degenerative Disc Disease
  • SI Joint Syndrome
  • Sciatica
  • Pinched Nerves and General Back Pain
  • And more
Learn More
Knee

Knees

Knees are the target of many common sports injuries. Sadly, they are also the target of a number of surgeries that research has frequently shown to be ineffective or minimally effective. Knee arthritis can also be a common cause for aging athletes to abandon the sports and activities they love. Regenerative procedures can be used to treat a wide range of knee injuries and conditions. They can even be used to reduce pain and delay knee replacement for more severe arthritis.

  • Knee Meniscus Tears
  • Knee ACL Tears
  • Knee Instability
  • Knee Osteoarthritis
  • Other Knee Ligaments / Tendons & Overuse Injuries
  • And more
Learn More
Lower Spine

Spine

Many spine injuries and degenerative conditions are good candidates for regenerative treatments and there are a number of studies showing promising results in treating a wide range of spine problems. Spine surgery should be a last resort for anyone, due to the cascade of negative effects it can have on the areas surrounding the surgery. And epidural steroid injections are problematic due to their long-term negative impact on bone density.

  • Herniated, Bulging, Protruding Discs
  • Degenerative Disc Disease
  • SI Joint Syndrome
  • Sciatica
  • Pinched Nerves and General Back Pain
  • And more
Learn More
Hand & Wrist

Hand & Wrist

Hand and wrist injuries and arthritis, carpal tunnel syndrome, and conditions relating to overuse of the thumb, are good candidates for regenerative treatments. Before considering surgery, consider an evaluation of your condition with a regenerative treatment specialist.
  • Hand and Wrist Arthritis
  • Carpal Tunnel Syndrome
  • Trigger Finger
  • Thumb Arthritis (Basal Joint, CMC, Gamer’s Thumb, Texting Thumb)
  • Other conditions that cause pain
Learn More
Elbow

Elbow

Most injuries of the elbow’s tendons and ligaments, as well as arthritis, can be treated non-surgically with regenerative procedures.

  • Golfer’s elbow & Tennis elbow
  • Arthritis
  • Ulnar collateral ligament wear (common in baseball pitchers)
  • And more
Learn More
Hip

Hip

Hip injuries and degenerative conditions become more common with age. Do to the nature of the joint, it’s not quite as easy to injure as a knee, but it can take a beating and pain often develops over time. Whether a hip condition is acute or degenerative, regenerative procedures can help reduce pain and may help heal injured tissue, without the complications of invasive surgical hip procedures.

  • Labral Tear
  • Hip Arthritis
  • Hip Bursitis
  • Hip Sprain, Tendonitis or Inflammation
  • Hip Instability
Learn More
Foot & Ankle

Foot & Ankle

Foot and ankle injuries are common in athletes. These injuries can often benefit from non-surgical regenerative treatments. Before considering surgery, consider an evaluation of your condition with a regenerative treatment specialist.
  • Ankle Arthritis
  • Plantar fasciitis
  • Ligament sprains or tears
  • Other conditions that cause pain
Learn More

Is Regenexx Right For You?

Request a free Regenexx Info Packet

REGENEXX WEBINARS

Learn about the #1 Stem Cell & Platelet Procedures for treating arthritis, common joint injuries & spine pain.

Join a Webinar

RECEIVE BLOG ARTICLES BY EMAIL

Get fresh updates and insights from Regenexx delivered straight to your inbox.

Subscribe to the Blog

FOLLOW US

Copyright © Regenexx 2019. All rights reserved. | Privacy Policy

*DISCLAIMER: Like all medical procedures, Regenexx® Procedures have a success and failure rate. Patient reviews and testimonials on this site should not be interpreted as a statement on the effectiveness of our treatments for anyone else.

Providers listed on the Regenexx website are for informational purposes only and are not a recommendation from Regenexx for a specific provider or a guarantee of the outcome of any treatment you receive.

LinkedIn
Email